1998 Legislation
Print Friendly

HOUSE BILL NO. 456 – Carisoprodol, controlled substance

HOUSE BILL NO. 456

View Daily Data Tracking History

View Bill Text

View Statement of Purpose / Fiscal Impact



Text to be added within a bill has been marked with Bold and
Underline. Text to be removed has been marked with
Strikethrough and Italic. How these codes are actually displayed will
vary based on the browser software you are using.

This sentence is marked with bold and underline to show added text.

This sentence is marked with strikethrough and italic, indicating
text to be removed.

Daily Data Tracking History



H0456........................................................by MR. SPEAKER
                Requested by: Idaho State Board of Pharmacy
CARISOPRODOL - CONTROLLED SUBSTANCE - Amends existing law to add
carisoprodol to the Schedule IV list of controlled substances.

01/12    House intro - 1st rdg - to printing
01/12    Rpt prt - to Health/Wel
01/27    Rpt out - rec d/p - to 2nd rdg
01/28    2nd rdg - to 3rd rdg
01/30    3rd rdg - PASSED - 59-6-5
      AYES -- Alltus, Barraclough, Bell, Bieter, Bivens, Black(15),
      Black(23), Boe, Bruneel, Callister, Campbell, Chase, Clark, Crane,
      Cuddy, Denney, Ellsworth, Field(13), Field(20), Gagner, Geddes,
      Hadley, Hansen, Henbest, Hornbeck, Jaquet, Jones(9), Jones(22), Judd,
      Kellogg, Kempton, Kendell, Kjellander, Kunz, Lake, Linford,
      Loertscher, Mader, McKague, Meyer, Miller, Newcomb, Pischner,
      Pomeroy, Reynolds, Robison, Sali, Stevenson, Stoicheff, Stubbs,
      Taylor, Tilman, Tippets, Trail, Watson, Wheeler, Wood, Zimmermann, Mr
      Speaker
      NAYS -- Barrett, Jones(20), Richman, Ridinger, Schaefer, Stone
      Absent and excused -- Alexander(Alexander), Crow, Deal, Gould,
      Mortensen
    Floor Sponsor - Boe, Henbest, Hornbeck
    Title apvd - to Senate
02/02    Senate intro - 1st rdg - to Health/Wel
02/23    Rpt out - rec d/p - to 2nd rdg
02/24    2nd rdg - to 3rd rdg
03/10    3rd rdg - FAILED - 11-23-1
      AYES--Bunderson, Danielson, Dunklin, Ingram, Lee, McLaughlin, Noh,
      Richardson, Stennett, Wheeler, Whitworth
      NAYS--Andreason, Boatright, Branch, Burtenshaw, Cameron, Crow,
      Darrington, Deide, Frasure, Geddes, Hansen, Hawkins, Ipsen, Keough,
      King, Parry, Riggs, Risch, Sandy, Schroeder, Sweeney, Thorne, Twiggs
      Absent and excused--Sorensen
    Floor Sponsor - Wheeler
    Filed with the Chief Clerk

Bill Text


H0456

                                                                        
 ||||              LEGISLATURE OF THE STATE OF IDAHO             ||||
Fifty-fourth Legislature                 Second Regular Session - 1998
                                                                        

                             IN THE HOUSE OF REPRESENTATIVES

                                    HOUSE BILL NO. 456

                                      BY MR. SPEAKER
                       Requested by: Idaho State Board of Pharmacy

 1                                        AN ACT
 2    RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT; AMENDING  SECTION  37-2711,
 3        IDAHO  CODE, TO ADD CARISOPRODOL TO THE LIST OF CONTROLLED SUBSTANCES CON-
 4        TAINED IN SCHEDULE IV.

 5    Be It Enacted by the Legislature of the State of Idaho:

 6        SECTION 1.  That Section 37-2711, Idaho Code, be, and the same  is  hereby
 7    amended to read as follows:

 8        37-2711.  SCHEDULE  IV.  (a)  Schedule  IV  shall consist of the drugs and
 9    other substances, by whatever official name, common or  usual  name,  chemical
10    name, or brand name designated, listed in this section.
11        (b)  Narcotic  drugs.  Unless  specifically  excepted  or unless listed in
12    another schedule, any material, compound, mixture, or  preparation  containing
13    any  of  the  following  narcotic drugs, or their salts calculated as the free
14    anhydrous base or alkaloid, in limited quantities as set forth below:
15        (1)  No more than 1 milligram of difenoxin and not less than 25 micrograms
16        of atropine sulfate per dosage unit;
17        (2)  Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,
18        2-diphenyl-3-methyl-2-propionoxybutane).
19        (c)  Depressants. Unless specifically excepted or unless listed in another
20    schedule, any material, compound, mixture, or preparation which  contains  any
21    quantity  of the following substances, including its salts, isomers, and salts
22    of isomers whenever the existence of such salts, isomers, and salts of isomers
23    is possible within the specific chemical designation:
24        (1)  Alprazolam;
25        (2)  Barbital;
26        (3)  Bromazepam;
27        (4)  Camazepam;
28        (5)  Chloral betaine;
29        (6)  Chloral hydrate;
30        (7)  Chlordiazepoxide;
31        (8)  Clobazam;
32        (9)  Clonazepam;
33        (10) Clorazepate;
34        (11) Clotiazepam;
35        (12) Cloxazolam;
36        (13) Delorazepam;
37        (14) Diazepam;
38        (15) Estazolam;
39        (16) Ethchlorvynol;
40        (17) Ethinamate;
41        (18) Ethyl loflazepate;
42        (19) Fludiazepam;
43        (20) Flurazepam;


                                          2

 1        (21) Halazepam;
 2        (22) Haloxazolam;
 3        (23) Ketazolam;
 4        (24) Loprazolam;
 5        (25) Lorazepam;
 6        (26) Lormetazepam;
 7        (27) Mebutamate;
 8        (28) Medazepam;
 9        (29) Meprobamate;
10        (30) Methohexital;
11        (31) Methylphenobarbital (mephobarbital);
12        (32) Midazolam;
13        (33) Nimetazepam;
14        (34) Nitrazepam;
15        (35) Nordiazepam;
16        (36) Oxazepam;
17        (37) Oxazolam;
18        (38) Paraldehyde;
19        (39) Petrichloral;
20        (40) Phenobarbital;
21        (41) Pinazepam;
22        (42) Prazepam;
23        (43) Temazepam;
24        (44) Tetrazepam;
25        (45) Triazolam;
26        (46) Quazepam;
27        (47) Zolpidem.
28        (d)  Fenfluramine - Any material, compound, mixture, or preparation  which
29    contains  any  quantity  of  the  following  substances,  including its salts,
30    isomers (whether optical, position, or geometric), and salts of such  isomers,
31    whenever  the existence of such salts, isomers, and salts of isomers is possi-
32    ble:
33        (1)  Fenfluramine.
34        (e)  Stimulants. Unless specifically excepted or unless listed in  another
35    schedule,  any  material, compound, mixture, or preparation which contains any
36    quantity of the following substances having a stimulant effect on the  central
37    nervous  system,  including  its salts, isomers (whether optical, position, or
38    geometric), and salts of such isomers whenever the existence  of  such  salts,
39    isomers,  and salts of isomers is possible within the specific chemical desig-
40    nation:
41        (1)  Cathine ((+)-norpseudoephedrine);
42        (2)  Diethylpropion;
43        (3)  Fencamfamin;
44        (4)  Fenproporex;
45        (5)  Mazindol;
46        (6)  Mefenorex;
47        (7)  Pemoline (including organometallic complexes and chelates thereof);
48        (8)  Phentermine;
49        (9)  Pipradrol;
50        (10) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
51        (f)  Other substances. Unless specifically excepted, or unless  listed  in
52    another  schedule,  any  material, compound, mixture or preparation which con-
53    tains any quantity of the following substance, including its salts:
54        (1)  Pentazocine ;
55        (2)  Carisoprodol .


                                          3

 1        (g)  The board may except by rule any compound,  mixture,  or  preparation
 2    containing  any  depressant substance listed in subsection (c) of this section
 3    from the application of all or any part of this act if the compound,  mixture,
 4    or  preparation contains one or more active medicinal ingredients not having a
 5    depressant effect on the central nervous system, and  if  the  admixtures  are
 6    included  therein in combinations, quantity, proportion, or concentration that
 7    vitiate the potential for abuse of the  substances  which  have  a  depressant
 8    effect on the central nervous system.

Statement of Purpose / Fiscal Impact


    





    STATEMENT OF PURPOSE
    RS07342
    Add to Idaho Code 37-2711 Schedule IV of the Uniform Controlled Substance Act
    Chapter 27, Title 37, the drug carisoprodol. This change is being requested because of
    the increased abuse of this drug. Restricts prescriptions for this drug to five refills or six
    months and will place it in the tracking system.
    
    
    FISCAL IMPACT
    No impact on the General Fund. No cost to the general public or practitioners.
    Implementation of legislation will be from the Board of Pharmacy dedicated funds.
    
    
    CONTACT
    Name: Richard K. Markuson, R.Ph.
    Agency: Idaho State Board of Pharmacy
    Phone: 334-2356
    Statement of Purpose/Fiscal Impact
    
    H 456